STAT Plus: With new combination drug data, Exelixis takes another shot at prostate cancer treatment

In 2014, the Bay Area biotech company Exelixis nearly shut down after its clinical trial for a prostate cancer drug ended in failure. A second attempt has delivered better, tumor-shrinking?

Click to view original post